Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna
VRAX•Focus on autoimmune and chronic immune conditions
The collaboration targets next-generation AOCs for autoimmune disease and chronic immune conditions, expanding beyond Veraxa’s core solid-tumor focus.
Next steps after milestone reached in under a year
Partners began talks on next steps following the proof-of-concept milestone achieved in under a year.
Positive in vitro proof-of-concept from Secarna alliance
Veraxa Biotech reported positive early in vitro results from its AOC research alliance with Secarna Pharmaceuticals.
An AOC candidate showed higher potency than the equivalent unconjugated oligonucleotide, supporting targeted antibody-guided delivery.
